Jupiter Neurosciences (NASDAQ: JUNS) has listed on the Nasdaq following a successful $11 million raise through its initial public offering (IPO).
The company offered 2,750,000 shares of common stock at a price of $4.00 per share.
Dominari Securities served as the lead underwriter for the offering, with Revere Securities acting as co-manager.
Use of IPO funds
The proceeds from the IPO will support Jupiter Neurosciences’ research and development efforts, including the advancement of JOTROL, an enhanced resveratrol formulation designed to treat neuroinflammation.
A portion of the funding will be directed towards a Phase II clinical trial for Parkinson’s Disease.
In addition, the company plans to allocate funds towards strategic service agreements in South-East Asia, exploration of new product opportunities, payment of outstanding license fees, debt repayment and general corporate purposes.
Future plans and research focus
Jupiter Neurosciences’ pipeline targets central nervous system (CNS) disorders and rare diseases.
The funding from the IPO will advance the company’s ambitious research agenda, including clinical trials for various conditions such as Alzheimer’s Disease, Parkinson’s Disease and Friedreich’s Ataxia.
The company specializes in tackling neuroinflammation through its platform product, JOTROL.
Jupiter’s pipeline includes treatments for CNS disorders and rare diseases, with potential applications in conditions such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia and MELAS.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.